Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 11—November 2021
Research

Changing Patterns of Disease Severity in Blastomyces dermatitidis Infection, Quebec, Canada

Alex CarignanComments to Author , Chiheb Boudhrioua, Sandrine Moreira, Andrée Ann Pelletier, Kevin Dufour, Jacques Pépin, Catherine Allard, Dominique Marcoux, and Philippe J. Dufresne
Author affiliations: Université de Sherbrooke, Sherbrooke, Quebec, Canada (A. Carignan, A.A. Pelletier, K. Dufour, J. Pépin, C. Allard, D. Marcoux); Laboratoire de Santé Publique du Québec, Sainte-Anne-de-Bellevue, Québec, Canada (C. Boudhrioua, S. Moreira, P.J. Dufresne)

Main Article

Table 2

Risk factors for 90-day all-cause mortality among patients with blastomycosis, Quebec, Canada*

Risk factor Survived, n = 155
 Died, n = 30 Crude odds ratio (95% CI)
 p value
 Adjusted odds ratio (95% CI)
 p value
Study period
1988–1997 31 (94) 2 (6) 1
1998–2007 47 (82) 10 (18) 3.3 (0.7–16.1) 0.1 2.7 (0.5–15.3) 0.3
2008–2017
 77 (81)
 18 (19)
 3.6 (0.8–16.6)
 0.1
 1.2 (0.2–6.5)
 0.8
Median no. days of symptoms before diagnosis (IQR)
 71 (26–141)
 37 (18–45)
 0.99 (0.99–1.00)
 0.04
 0.99 (0.99–1.00)
 0.07
Median age, y (IQR)
 54 (44–64)
 62 (53–71)
 1.04 (1.01–1.07)
 0.004
 1.04 (1.00–1.07)
 0.04
Sex
F 34 (81) 8 (19)
M
 121 (85)
 22 (15)
 0.8 (0.3–1.9)
 0.6
Charlson Comorbidity Index score
0 76 (94) 5 (6)
1–2 43 (81) 10 (19) 3.5 (1.1–16.1) 0.03
≥3
 36 (71)
 15 (29)
 6.3 (2.1–18.8)
 0.001
Underlying condition
Diabetes 23 (72) 9 (28) 2.5 (1.00–6.04) 0.05
COPD 27 (79) 7 (21) 1.4 (0.6–3.7) 0.5
Immunosuppression
 27 (61)
 17(39)
 6.2 (2.7–14.3)
 <0.001
 4.2 (1.5–11.6)
 0.005
No. organs involved
1–2 105 (87) 16 (13)
>2
 50 (78)
 14 (22)
 1.8 (0.8–4.1)
 0.1
Radiologic manifestations
No. lobes
0–2 112 (93) 8 (7)
>2 43 (66) 22 (34) 7.2 (3.0–17.3) <0.001 5.3 (1.9–14.3) 0.001
Miliary presentation
 6 (67)
 3 (33)
 2.8 (0.7–11.7)
 0.2
First antifungal received
Amphotericin, lipid formulations 20 (80) 5 (20) 1
Amphotericin B, deoxycholate 13 (76) 4 (24) 1.2 (0.3–5.5) 0.08
Azole 107 (96) 4 (4) 0.1 (0.04–0.61) 0.008
No treatment 15 (47)
 17 (53) 4.5 (1.4–15.1)
 0.01

*Values are no. (%) except as indicated. COPD, Chronic obstructive pulmonary disease; IQR, interquartile range.

Main Article

Page created: September 11, 2021
Page updated: October 19, 2021
Page reviewed: October 19, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external